Trials and Fibrillations with Dr John Mandrola

 
 

Trials and Fibrillations with Dr John Mandrola

  • The Case Against Thrombolytic Therapy in Stroke A New York Times article siding with neurologists in their debate with emergency medicine over the benefits of tPA in ischemic stroke prompted Dr Mandrola to take a closer look at the data.
  • Pharmacists and Barbers on the Cutting Edge of Medicine Dr Mandrola's hands-down favorite study from the 2018 American College of Cardiology meeting showed that a pharmacist-led intervention in black-owned barbershops cut hypertension in black men.
  • ACC 2018 Ten Quick Thoughts on ODYSSEY Despite a suggested mortality benefit for the PCSK9 inhibitor alirocumab, in high-risk ACS patients, a return to lipid targets may be the cost-effective lesson from this trial, argues Dr Mandrola.
  • ACC 2018 The VEST Trial Failed, and So Did the Press Release The first randomized trial on the wearable cardioverter defibrillator didn't meet its primary endpoint, yet the press release was overly positive.
  • Mandrola Previews 2018 ACC PCSK9 inhibitors, LifeVest, and his-bundle pacing are among Dr Mandrola's picks for what to look for at the 2018 American College of Cardiology Scientific Sessions.
  • Donald Trump Has Coronary Calcium: Is That Helpful to Know? A briefing on the President's health included the detail that he has a coronary artery calcium score of 133. Dr Mandrola questions whether Trump should have even had a calcium scan.
  • Nine Things to Remember About CASTLE-AF Ablation of atrial fibrillation in patients with heart failure lowered all-cause mortality in this trial, but Dr Mandrola urges electrophysiologists not to overextrapolate these impressive results.
  • Flawed Surgical Left Atrial Appendage Closure Study Oversold An observational study on surgical left atrial appendage closure prompts Dr Mandrola to bemoan the overreach of the authors and editorialist.
  • Mandrola's Top 10 Cardiology Stories of 2017 Controversy surrounding saturated fat and sham PCI make this year's list as well as a few medical reversals and the continuing opioid crisis. What topics would you add or omit?
  • Overdiagnosis Only a Matter of Time With ECG Watches An Apple Watch with an ECG reader may be fun for specific tasks, but it's fantasy to think it will improve health outcomes, according to this electrophysiologist.
  • AHA Better Patient Decisions: A Destination Within Reach A study showing that a comprehensive decision aid could help patients make treatment choices in line with their values is Dr Mandrola’s favorite trial of AHA 2017.
  • AHA What if Quality Measures Increased Mortality? Dr Mandrola reports on a provocative study showing that reducing readmissions for heart failure associates with higher mortality.
  • AHA Ushering in a New Era of Disease Prediction Dr Mandrola attended a young investigators award session and reports on the future of risk prediction--which means knowing our DNA.
  • TCT Seven Reasons New Data on Watchman Are Not Persuasive PREVAIL 5-year data and a patient-level meta-analysis nudge the Watchman left atrial appendage device to meeting noninferiority, but the devil is in the details, notes Dr Mandrola.
  • AHA Mandrola Previews AHA 2017 The American Heart Association Scientific Sessions begin in Anaheim November 11. Learn which updates Dr Mandrola is most looking forward to.
  • Coronary Stents Humbled Yet Again in Stable CAD ORBITA, a sham-control PCI trial, found no angina benefit for stents in patients with stable CAD. Ten years after COURAGE, it's high time cardiologists treat patients, not lesions, pleads Dr Mandrola.
  • TCT Will I Feel Better? QoL Outcomes Make the Big Stage at TCT A quality-of-life substudy of a trial comparing coronary stenting and bypass surgery could herald a new era of truly patient-centered decision-making, hopes Dr Mandrola.
  • We Need Consistency, Not Complacency, to Improve Public Health Obesity has been normalized to become the problem clinicians don't see and therefore don't treat, but recent data showing that one in five kids and teens are obese should shock us into action, says Dr Mandrola.
  • Positive Results for PFO Closure Come With Caveats Three studies give PFO closure in cryptogenic stroke a boost, but patient selection is critical, and let's not forget about direct oral anticoagulants, cautions Dr Mandrola.
  • Pacemaker Hacking: Good TV Plot, but Not Worth Alarming Patients A cybersecurity vulnerability leaves some pacemakers susceptible to hacking, but this remote possibility does not warrant the risk of the fix and unnecessarily worrying patients, argues Dr Mandrola.
learn more

link

in detail steroid-pharm.com